Monoclonal antibody production demands more than available capacity. It requires a manufacturing partner with deep process expertise, a strong regulatory track record and the operational discipline to deliver consistent quality at every scale.
AbbVie offers end-to-end biologics contract manufacturing services designed to accelerate your monoclonal antibody program from first-in-human through commercial launch and lifecycle management.
Our process development teams deliver upstream and downstream process development, optimization and scale-up services. Capabilities include:
Cell culture process development and optimization
Purification process development
Media development and optimization
Analytical method development
Extended product characterization
Viral clearance studies
AbbVie operates cGMP manufacturing with flexible scale options to match your program requirements:
2,000L single-use bioreactors (SUBs) for early clinical and smaller commercial batches
3,000L and 6,000L stainless steel options for mid-scale production
12,000L stainless steel capacity for large-scale commercial manufacturing
Our manufacturing network spans three globally approved sites: Worcester, Massachusetts (ABC), Barceloneta, Puerto Rico (ABL) and Martillac, France (MBM)—providing geographic flexibility and supply chain resilience.
Pre-clinical to commercial mAb manufacturing, from 2,000L to 12,000L batch sizes
AbbVie offers world-class monoclonal antibody manufacturing in the US, Europe and Singapore. Capabilities include 2,000L single use bioreactors (SUBs), and 3,000L, 6,000L and 12,000L stainless steel equipment options in various suite configurations. The illustration below offers various examples of our ability to initiate partnership at any stage of your product development, up to and including ongoing commercial supply.
Beyond traditional monoclonal antibodies, AbbVie Contract Manufacturing has validated experience across complex mammalian modalities:
Monoclonal antibodies (mAb)
Bispecific and trispecific (Multispecific) antibodies
Fc fusion proteins
This breadth of experience means our technical teams understand the unique challenges of complex molecule manufacturing—from expression system optimization through formulation development.
Every mAb manufacturing program is supported by comprehensive analytical capabilities:
HPLC (SEC, IEX, affinity, reverse phase)
Host cell protein analysis
Electrophoresis (CE, IEF, SDS-PAGE)
ELISA
Peptide structure determination (LC, MS)
Oligosaccharide analysis
DNA quantification and identification
Spectrophotometry (FT-IR, UV VIS)
Bioburden and endotoxin testing
Our quality systems reflect AbbVie's global pharmaceutical standards, with commercial approvals in 180+ countries and a strong track record of successful regulatory inspections.
AbbVie is uniquely positioned to support your extended supply chain from drug substance through drug product. Our aseptic fill-finish capabilities in Sligo, Ireland include state-of-the-art isolator technology for both liquid and lyophilized vial presentations (2R-20R).
For ADC programs, we offer fully integrated manufacturing from antibody intermediate through conjugation and final drug product—all within a single quality and operational network.
Patient-centered culture: Every project is treated with the same urgency and quality standards as AbbVie's own products
Operational leadership: Access to the planning, supply chain and sourcing capabilities that support AbbVie's global commercial portfolio
Long-term commitment: 40+ years of sustained investment in contract manufacturing capabilities
Strategic partnership: We focus on fewer partners within our core competencies, offering dedicated resources and clear project visibility
